Financial Performance - The net profit attributable to the parent company was CNY 108,394,751.90, an increase from CNY 67,017,224.47 in the previous period, representing a growth of approximately 62%[1] - The total comprehensive income attributable to the parent company was CNY 103,419,463.93, compared to CNY 63,941,727.19 in the previous period, indicating an increase of about 62%[1] - Basic and diluted earnings per share were both CNY 0.27, up from CNY 0.18 in the previous period, reflecting a growth of 50%[1] - The company's revenue for the reporting period reached ¥367,275,121.57, an increase of 29.24% compared to ¥284,171,341.73 in the same period last year[20] - Net profit attributable to shareholders was ¥108,394,751.90, reflecting a 61.74% increase from ¥67,017,224.47 year-over-year[20] - Net profit for Q1 2023 was CNY 108,394,751.90, compared to CNY 67,017,224.47 in Q1 2022, representing a 61.7% increase[44] Cash Flow - Cash inflow from operating activities totaled CNY 404,771,442.02, compared to CNY 339,480,490.18 in the previous period, marking an increase of approximately 19%[6] - The net cash flow from operating activities was CNY 62,825,635.11, significantly higher than CNY 29,853,643.99 in the previous period, representing a growth of over 110%[6] - The company reported a net increase in cash and cash equivalents of CNY 174,442,271.83, contrasting with a decrease of CNY 15,496,972.96 in the previous period[9] - The company received CNY 706,100,421.72 related to investment activities, a significant rise from CNY 39,936,515.20 in the previous period[6] - The net cash flow from investment activities was CNY 114,324,666.69, compared to a negative cash flow of CNY 117,815,481.68 in the previous period, showing a turnaround[6] - The company received tax refunds amounting to CNY 11,798,215.29, compared to CNY 7,815,535.11 in the previous period, reflecting an increase of approximately 50%[6] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,447,336,837.03, a 1.74% increase from ¥3,388,446,632.86 at the end of the previous year[20] - The total current liabilities decreased, with accounts payable dropping to CNY 143,430,712.32 from CNY 160,450,737.62, a reduction of approximately 10.6%[38] - The company's total liabilities decreased to CNY 322,536,513.02 from CNY 367,065,772.78, showing improved financial health[44] - The total equity attributable to shareholders reached CNY 3,124,800,324.01, up from CNY 3,021,380,860.08, reflecting growth in shareholder value[44] Operational Efficiency - The company completed the relocation of its registered office, which may facilitate operational efficiency[33] - Management expenses increased by 40.84% to ¥18,505,031.84, attributed to an increase in management personnel and average salaries[24] - The company reported a gross profit margin improvement, with gross profit for the period calculated at CNY 115,310,643.28, compared to CNY 74,195,240.62 in the previous year[44] Investments and Innovations - The company approved an investment of CNY 224,789,100 in the construction of the Meihua Chuangyi Building project using raised funds[34] - The company received two medical device registration certificates on March 6, 2023, valid until March 5, 2028, enhancing its product portfolio[35] - The company's investment income surged by 11,154.43% to ¥4,054,463.25, primarily from bank financial products[24] - Research and development expenses were CNY 20,709,769.49, an increase from CNY 17,150,460.88, indicating a focus on innovation[44] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[46]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于2023年4月 18日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于2023年4月26 日（星期三）15:00-16:00在全景网举办"2022年度网上业绩说明会"，本次业绩 说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次业绩说明会。 为充分听取投资者的意见和建议，提升交流的针对性，现就公司本次业绩说 明会提前向广大投资者公开征集问题，投资者可于2023年4月26日（星期三）12:00 前访问https://ir.p5w.net/zj/，或扫描下方二维码进入问题征集专题页面。公 司将在本次业绩说明会上，对投资者普遍关注的问题进行回答。在业绩说明会期 间，投资者仍可登陆活动界面进行互动提问。 （二维码放置） 证券代码：301363 证券简称：美好医疗 公告编号：20 ...

证券代码：301363 证券简称：美好医疗 公告编号：2023-037 深圳市美好创亿医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 出席本次网上业绩说明会的人员有：公司董事长兼总经理熊小川先生，副 董事长兼副总经理袁峰先生，董事兼副总经理周道福先生，独立董事王建新先 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于2023年4月 18日在巨潮资讯网（www.cninfo.com.cn）披露了《2022年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于2023年4月26 日（星期三）15:00-16:00在全景网举办"2022年度网上业绩说明会"，本次业绩 说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次业绩说明会。 为充分听取投资者的意见和建议，提升交流的针对性，现就公司本次业绩说 明会提前向广大投资者公开征集问题，投资者可于2023年4月25日（星期二）12:00 ...

证券代码：301363 证券简称：美好医疗 编号：2022-001 深圳市美好创亿医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者 关系活 动类别 | 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 现场参观 | □路演活动 其他（电话会议） | | 活动参 与人员 | 详见附件一清单 | | | 时间 | 1 、电话会议： 2022 2 、现场参观： 2022 | 年 11 月 8 ...

深圳市美好创亿医疗科技股份有限公司 2022 年第三季度报告 证券代码：301363 证券简称：美好医疗 公告编号：2022-002 深圳市美好创亿医疗科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 深圳市美好创亿医疗科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|---------------------|----------------- ...